Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

The Expression of Telomerase Reverse Transcriptase Protein is an Independent Prognostic Marker in Early Stage Non-Small Cell Lung Carcinomas

´ëÇѺ´¸®ÇÐȸÁö 2007³â 41±Ç 2È£ p.95 ~ 102
Á¤ÁöÇÑ, Á¤Âù±Ç, À̾ƿø, ¹Ú°æ½Å, À¯Áø¿µ, À̱³¿µ,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤ÁöÇÑ ( Jung Gee-Han ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»óº´¸®°úÇб³½Ç

Á¤Âù±Ç ( Jung Chan-Kwon ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»óº´¸®Çаú
À̾ƿø ( Lee Ah-Won ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»óº´¸®Çб³½Ç
¹Ú°æ½Å ( Park Gyeong-Sin ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
À¯Áø¿µ ( Yoo Jin-Young ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
À̱³¿µ ( Lee Kyo-Young ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


Background: The catalytic subunit of telomerase, hTERT (telomerase reverse transcriptase), is one of the most important components of telomerase, and performs a pivotal role in the mechanism underlying the regulation of telomerase activity in cellular immortalization and carcinogenesis. The principal objective of this study was to investigate hTERT expression in patients with non-small cell lung carcinomas (NSCLCs), and to evaluate its clinical significance and association with the expression of p16 and p53.

Methods: Using tissue microarray, the protein expression profiles of hTERT, p16 and p53 were investigated via immunohistochemistry in 167 samples of NSCLCs.

Results: Expression was observed in 54.5% (91/167) of the tumors, which were predominantly squamous cell carcinomas. Patients evidencing hTERT expression in their tumors exhibited significantly poorer survival rates than did patients without hTERT expression in early-stage NSCLCs (p=0.0125). According to the results of our Cox regression analysis, hTERT expression proved to be an independent prognostic factor (p= 0.006), particularly for squamous cell carcinomas (p=0.019). hTERT expression was not correlated with p16 expression, but was rather associated with the expression of p53 (p=0.002).

Conclusion: Our results show that hTERT may perform a function in the progression of NSCLC, and that its detection may be useful in predicting the prognosis of NSCLC patients in the early stages of the disease, as well as in the development of a targeted therapy in these tumors.

Å°¿öµå

Telomerase reverse transcriptase; Carcinoma; Non-small cell lung; Prognosis

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS